Abbisko Therapeutics - 上海和誉生物医药科技有限公司-LIST

Press Releases

Abbisko is going to disclose two pre-clinical research results at the 35th EORTC-NCI-AACR Conference

Sep 20, 2023

Abbisko Therapeutics published breakthrough translational research results of FGFR4 inhibitors on an AACR journal “Molecule Cancer Therapeutics”

Sep 18, 2023

Abbisko Therapeutics Obtained Approval from Europe EMA for Pivotal Global Multi-Center Phase III Clinical Trial of CSF-1R Inhibitor Pimicotinib (ABSK021)

Sep 11, 2023

VOLUNTARY ANNOUNCEMENT THE SHAREHOLDING OF THE FOUNDERS OF THE COMPANY

Aug 29, 2023

Milestone — Abbisko Therapeutics Completes the First Patient Dose in US Phase III TGCT Trial of in CSF-1R Inhibitor – Pimicotinib（ABSK021）

Aug 02, 2023

Abbisko will present clinical results of two First-in-Human Studies at the 2023 European Society for Medical Oncology（ESMO）

Jul 31, 2023

Abbisko Therapeutic announces the IND approval by U.S. FDA for its next-generation EGFR-Exon20 inhibitor ABSK112

Jul 05, 2023

Abbisko Therapeutics Announces First Patient Dosed in Phase II Trial of CSF-1R Inhibitor – Pimicotinib（ABSK021）for cGVHD.

Jun 12, 2023

Abbisko Therapeutics announces that Europe EMA has granted Priority Medicine designation for its CSF-1R inhibitor Pimicotinib（ABSK021）

Jun 08, 2023

Abbisko to present updated Phase Ib clinical results of Pimicotinib (ABSK021）in patients with advanced TGCT at the 2023 ASCO annual meeting

May 29, 2023

Abbisko Therapeutics Completes the First Patient Dose in Global Phase III Trial of CSF-1R Inhibitor – Pimicotinib（ABSK021）

Apr 27, 2023

Abbisko presents 5 research results at the 2023 AACR Annual Meeting

Apr 17, 2023

Abbisko Therapeutic announces that its next-generation FGFR4 mutant inhibitor ABSK012 has been granted orphan drug designation in the US for the treatment of Soft Tissue Sarcoma

Apr 03, 2023

Abbisko Therapeutics Obtained Approval from U.S. FDA for Pivotal Global Multi-center Phase III Clinical Trial of CSF-1R Inhibitor Pimicotinib (ABSK021)

Mar 16, 2023

Abbisko Therapeutics Announces an Out-License Agreement with Allist for ABK3376

Mar 01, 2023

Abbisko therapeutic announces the IND approval by NMPA for its next-generation FGFR inhibitor ABSK121

Feb 22, 2023

EXPANDED ACCESS POLICY

Feb 01, 2023

Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib（ABSK021）

Jan 30, 2023

Abbisko Therapeutics Obtains Approval from The China NMPA to Conduct a Phase II Clinical Study of Pimicotinib (ABSK021）in cGVHD

Jan 17, 2023

Abbisko Therapeutics announces preliminary Phase I safety and efficacy results of Irpagratinib (ABSK011) in patients in second-line hepatocellular carcinoma with FGF19 overexpression

Dec 15, 2022

Abbisko Therapeutics announces preliminary Phase II safety and efficacy results of Fexagratinib (ABSK091) in patients with urothelial carcinoma

Dec 08, 2022

Preliminary Phase Ib results of ABSK021 for advanced TGCT will be published at the 2022 CTOS annual meeting

Nov 15, 2022

Abbisko Therapeutics completed the first patient enrollment in the Phase II clinical trial for ABSK091 in combination with BeiGene’s Tislelizumab in urothelial carcinoma

Nov 04, 2022

Abbisko Therapeutic announces the clinical trial approval granted by U.S. FDA for its next-generation FGFR inhibitor ABSK121

Nov 01, 2022

Abbisko Therapeutics obtained pivotal Phase III clinical trial approval for CSF-1R inhibitor ABSK021 from the CDE of NMPA

Oct 25, 2022

Abbisko Therapeutics Completed Dosing of First Patient in China for Its Small-Molecule PD-L1 Inhibitor ABSK043

Sep 27, 2022

Abbisko Therapeutics won the 2022 "Future Star" Award of the biopharmaceutical industry

Aug 15, 2022

Abbisko Therapeutics announces China NMPA breakthrough therapy designation granted for its CSF-1R inhibitor ABSK021

Jul 20, 2022

Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061

Jul 04, 2022

Abbisko Therapeutics Announces the Appointment of Dr. Zidong Zhang as CFO

May 16, 2022

Abbisko Therapeutics Declared Two Next-Generation Precision Oncology Preclinical Candidates and Will Present Multiple Discovery and Translational Research Results at AACR Annual Meeting 2022

Mar 11, 2022

Abbisko Therapeutics Has Obtained IND Approval for ABSK061, an Innovative and Highly Selective FGFR2/3 Inhibitor, from the NMPA

Mar 03, 2022

Abbisko Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate ABSK091 in Combination with Tislelizumab

Feb 15, 2022

Abbisko Therapeutics Completes Dosing of the First Patient in the Phase II Clinical Trial for ABSK011 in Combination with an Anti-PD-L1 Antibody

Feb 08, 2022

View all

we discover and develop first-in-class and best-in-class therapies

to address critical unmet needs for cancer patients in China and globally

Media

TIME: The FDA has approved the CSF-1R inhibitor Pimicotinib (ABSK021) of Abbisko Therapeutics to enter the Pivotal Global Multi-center Phase III Clinical Trial.

Mar 17, 2023

HEALTHY GEM：Abbisko Therapeutics Announces An Out-License Agreement With Allist For ABK3376

Mar 17, 2023

Bioworld：FDA grants breakthrough therapy designation to Abbisko's CSF 1R inhibitor, pimicotinib

Jan 30, 2023

Bioworld：Abbisko out-licenses preclinical EGFR candidate to Allist for $188M

Mar 03, 2023

AP NEWS: Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib（ABSK021）

Jan 31, 2023

TIME: Abbisko Therapeutics Obtains Approval from The China NMPA to Conduct a Phase II Clinical Study of Pimicotinib (ABSK021） in cGVHD

Jan 19, 2023

Abbisko Therapeutics Obtained ABSK091 IND Approval from NMPA

Dec 14, 2020

Abbisko Therapeutics’ Partner X4 Pharmaceuticals Presented Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome

Jun 19, 2020

Abbisko Therapeutics Completes Dosing of the First Patient Cohort for ABSK-021 and The First Patient Enrollment for ABSK-011

Apr 07, 2020

Abbisko Therapeutics Enters into Licensing Agreement with AstraZeneca for Development and Commercialization of AZD4547

Nov 08, 2019

View all